Target tyrosine kinases / Inhibit EGFR / Comparison
STIs that target Bcr-Abl and EGFR
Comparison
IMATINIB (CML) |
GEFITINIB (NSCLC) |
|
Understanding of the genetic defects |
Excellent |
Poor |
Homogeneity of disease process among candidate patients ("likely responders") |
Yes, among patients in chronic phase |
No |
Uniqueness of drug target (molecular markers) |
Only in cancer cells |
In many normal and cancer cells |
Large scale success |
Yes |
Not really (fails more often than it works) |